Glucotrack receives second Nasdaq delisting notice for failing minimum stockholders' equity
GCTK is trading near its 52-week low of $0.58 (9.5% above the low) on light trading volume (0.1× avg).
Summary
Glucotrack received a second delisting notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, compounding its existing bid price deficiency and increasing delisting risk.
Key Events · Legal and Risk Events · GCTK
-
Second Delisting Notice Received
Nasdaq notified Glucotrack of non-compliance with the $2.5 million minimum stockholders' equity requirement, identified from the Q1 2026 Form 10-Q.
-
Additional Basis for Delisting
This new deficiency serves as an additional and independent basis for delisting from The Nasdaq Capital Market, compounding the existing bid price rule violation.
-
Appeal Process Initiated
The company intends to request a hearing before a Nasdaq Hearings Panel by May 18, 2026, to appeal both delisting determinations, which will temporarily stay delisting actions.
Analysis · GCTK · Industrial Applications And Services
This 8-K confirms Glucotrack's precarious financial position, adding a second, independent reason for delisting from Nasdaq. The company previously received a notice for failing the minimum bid price rule. Now, Nasdaq has identified a failure to meet the $2.5 million minimum stockholders' equity requirement, as revealed in the recent 10-Q. This significantly increases the risk of delisting, despite the company's intent to appeal.
At the time of this filing, GCTK was trading at $0.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.58 to $15.90. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.